Background: Fibromyalgia is a complex chronic disorder with few effective treatments currently available. One promising treatment option is repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique that has shown promise in disorders effecting the central nervous system. Methods: We assessed the efficacy of a course of high-frequency (10 Hz) left-hemisphere dorsolateral prefrontal cortex (DLPFC) rTMS in 26 patients (14 active; 12 sham) with a diagnosis of fibromyalgia. Participants underwent a double-blind stimulation protocol of daily (Monday-Friday) rTMS sessions over four consecutive weeks (total of 20 sessions; 75 9 4-s 10 Hz trains at 120% resting motor threshold). Assessments were conducted at baseline, 4 weeks and at 1-month follow-up. Results: Using mixed-model analysis we did not identify a group difference for our primary outcome measures. However, we found that patients in the active group compared to sham treatment group had significantly greater improvement in the Physical Fatigue (p = 0.045) and General Fatigue (p = 0.023) scales of the Multidimensional Fatigue Inventory-20 at the 1 month follow-up. In a responder analysis, we also found the active group was significantly more likely (2.84 times) to achieve a minimum 30% improvement in pain intensity ratings. (p = 0.024). Conclusions: High-frequency rTMS applied daily for 4 weeks to the left DLPFC induces significant relief from fatigue and a greater chance of clinically meaningful improvement in pain intensity in patients with fibromyalgia. These results suggest DLPFC rTMS may be a relevant therapy for fibromyalgia. Significance: This study provides evidence that 4-weeks of daily rTMS to the left DLPFC is able to improve fatigue in fibromyalgia. This novel finding provides impetus for the further investigation of the utility of TMS approaches for the relief of fatigue, an otherwise difficult-to-treat symptom, in fibromyalgia and related disorders.
Introduction
Fibromyalgia is a common musculoskeletal condition affecting around 1-3% of the general population worldwide (Wolfe et al., 1995) . It is defined as a complex chronic disorder characterized by widespread musculoskeletal pain and tenderness, often accompanied by additional features including fatigue, sleep disturbance and cognitive dysfunction (Wolfe et al., 2016) and is associated with co-occurring health issues including mood disorders (Wolfe et al., 1990; Mease et al., 2005) . As the aetiology of fibromyalgia remains unclear, there is no single disease-specific treatment available for the disorder. In addition, there is an absence of evidence to support the current commonly used treatments for fibromyalgia (Goldenberg, 2016) . For example, in the limited instances of support for pharmacological intervention (e.g. gabapentin and pregabalin), clinically meaningful effects are only seen in a minority of patients (Moore et al., 2014) . This may result, in part, from the fact that the side effects of such medications require them to be administered at a subtherapeutic dose (Zaghi et al., 2010) . Despite this, pharmaceutical methods remain the mainstay treatment, with non-steroidal anti-inflammatory drugs, opioid analgesics, antidepressants or anticonvulsants most commonly prescribed (Ashburn and Staats, 1999) .
There is, however, a growing body of research implicating a crucial role for central nervous system (CNS) dysfunction in fibromyalgia, as evidenced by changes in brain structure (Kuchinad et al., 2007; Lutz et al., 1998) , function (Giesecke et al., 2005; Gracely et al., 2004; Malinen et al., 2010) , neurophysiology (Mhalla et al., 2010) and neurochemical (Harris et al., 2007) processes. One potentially critical process may be central sensitization (increased excitability of neurons), which appears likely to be related to changes in the action of the excitatory neurotransmitter glutamate acting at N-methyl D-aspartate (NMDA) receptors (Bellato et al., 2012) . A promising avenue through which to modulate this aberrant brain activity is neuromodulation, such as repetitive transcranial magnetic stimulation (rTMS). rTMS describes the repeated application of transcranial magnetic stimulation (TMS), which a safe and non-invasive procedure that involves the use of a time variable, intense (~2 Tesla) and focused magnetic field to induce an electrical field in superficial regions of the brain (Barker et al., 1985) . The induction of this magnetic field produces depolarization of neurons in the brain, with repeated firing of neurons over time changing their activity (Fitzgerald et al., 2006) . The use of rTMS in clinical populations is most robustly established in treatment-resistant major depression (e.g. O'Reardon et al., 2007; Schutter, 2009; Slotema et al., 2010) and has been approved for therapeutic use by the FDA since 2008.
In several recent reviews of rTMS for fibromyalgia (Marlow et al., 2013; Knijnik et al., 2015; Hou et al., 2016) , it was identified that rTMS has some, albeit limited, benefit on multiple symptom domains compared to sham rTMS. The latest of these reviews identified a total of 11 studies in their search criteria. Critically, these reviews all concluded that there exist an insufficient number of methodologically rigorous studies to verify rTMS as an effective treatment for fibromyalgia, or to identify optimization of parameters for best outcomes. In particular, the studies to date were limited by the heterogeneity of design (frequency and site of stimulation has varied, with the majority of studies stimulating the motor cortex), treatment course (on average~13 sessions applied over 2 to 21 weeks), potentially restrictive assessment of the symptom profile of fibromyalgia, as well as small sample size (for further discussion, see Fitzgibbon et al., 2016) . In addition, the ecological validity of the studies of the studies to date is questioned given limiting exclusion criteria (i.e. female only samples).
In the current study, we investigated the clinical efficacy of a 4-week sham-controlled rTMS treatment course applied to the left dorsolateral prefrontal cortex (DLPFC) in patients with fibromyalgia. In doing so, we aimed to address some of the limitations of the work to date. Namely, we provided a daily (Monday to Friday) treatment course for 4 weeks, one of the longest acute treatment courses in this population to date. In addition, we targeted a brain region that has received relatively less attention than the motor cortex, the DLPFC, for the treatment of fibromyalgia (4/11 randomized rTMS trials, see Hou et al., 2016) . The DLPFC was selected as it is believed to be a key area in the regulation of pain perception through the direct modulation of corticosubcortical and corticocortical pathways. This has been suggested to occur through top-down inhibition of pain-related pathways (Lorenz et al., 2003; Wiech et al., 2008) . In addition to its role in the experience of pain, the DLPFC also plays a role in symptoms implicated in fibromyalgia, including mood and fatigue, most likely reflecting the region's role as a key node in several cognitive, affective and sensory networks (Seminowicz and Moayedi, 2017) . Thus, alongside in-depth outcome measures in alignment with rTMS for pain guidelines (Klein et al., 2015) , this study intended to address the direct effects of rTMS effects on fibromyalgia as a syndrome rather than a pain disorder alone.
Methods

Study design
The study was a randomized double-blind placebocontrolled trial with randomization to active or sham rTMS treatment. Randomization occurred through a computer number sequence by an independent researcher not involved in the rTMS administration or outcome assessments, who then coordinated sequentially numbered envelopes with blinding allocation concealed within. Patients and raters were blind to the treatment allocations. Treatment involved a total of 20 rTMS sessions applied Monday to Friday over four consecutive weeks and conducted at Monash Alfred Psychiatry Research Centre. Participants completed outcomes measures at baseline, at the end of each treatment week and at the one-month follow-up. Participants and treaters were unblinded after completion of the one-month follow-up and patients who had undergone sham rTMS were offered active rTMS. Written informed consent was obtained from all patients, and the study was approved by the Human Ethics Committee of Alfred Health, Monash University and Monash Health. The study was prospectively registered with the Australian New Zealand Clinical Trials Registry http:// www.anzctr.org.au/ (ACTRN12613000561785).
Subjects
There were 26 adults randomized (see Table 1 for demographic and baseline characteristics). Of the 26 participants randomized, 14 were allocated to active and 12 to sham rTMS (see Fig. 1 ), and 23 completed treatment (12 active; 11 sham). Following randomization, three patients (12%) withdrew from the study; one withdrew post baseline assessment due to fatigue, and two withdrew during treatment due to poor tolerance to treatment (one allocated to active, one to sham). All patients who were randomized (n = 26) were included in an intention-to-treat analysis. We had a planned enrolment of 40 patients; however, we concluded the trial at 26 as we had exceeded the planned interval of the study and had secured funding for a next step investigation.
Patients were recruited through the research team's existing databases and advertisements in the local community between 2013 and 2017. All had a formal diagnosis of Fibromyalgia according to American College of Rheumatology 2010 criteria (Wolfe et al., 2010) and were consistent with 2016 diagnostic revisions (Wolfe et al., 2016) . In the instance of any diagnostic uncertainty, patients were referred to the study rheumatologists for diagnostic confirmation (EG, GL). Patients were required to have had symptoms >6 months, at least mild to moderate symptoms based on an approximate total score >39 on the Fibromyalgia Impact Questionnaire and/or 4 or greater on the pain severity scale of the Brief Pain Inventory, and to have had no change in therapeutic management (pharmacological or non-pharmacological) in the four weeks prior to rTMS commencement or during trial enrolment. Patients were excluded if they had TMS contraindications (including epilepsy or history of seizure, pacemakers and other implantable medical devices, serious head injury, and pregnancy) as well as history or diagnosis of neurological and/or psychiatric illness and specific pathological entities, such as infection, neoplasm, metastasis, osteoporosis or fracture, or additional major musculoskeletal conditions. Given the high comorbidity of depression and anxiety in fibromyalgia (see Thieme et al., 2004) , patients were only excluded if they concurrently met criteria for a formal diagnosis of major depressive episode or comorbid anxiety disorder (assessed through the Mini International Neuropsychiatry Interview Screen Sheehan et al., 1998) and/or where these disorders were considered the primary complaint of the patient. Similarly, participants were not excluded based on medication use, unless unsafe for rTMS as determined by the study medical doctor (PF).
rTMS treatment
rTMS was administered using either the NeuroStar TMS Therapy System (Neuronetics Inc) or the MagVenture Magpro30 magnetic stimulator, with individual treatment courses conducted on the same machine. Resting motor threshold (RMT) was assessed using standard methods (Pridmore et al., 1998) , determined by the lowest intensity to induce a motor-evoked potential (MEP) of 50 lV in three of five trials with the coil placed with the handle pointing back and away from the midline at 45 degrees and tangential to the scalp. Where the NeuroStar was used, RMT was determined using MT Assist software (Neuronetics Inc.).
Treatment stimulation site was the left-hemisphere DLPFC (studies have shown left DLPFC stimulation demonstrates bilateral effects on the pain system (Brighina et al., 2011) ) identified as 'F3' using the EEG 10:20 system method. Patients randomized to the active rTMS group received 75 trains of 4-s duration (total pulses = 3000, intertrain interval of 21, total treatment duration 31.25 min) at a frequency of 10 Hz. Stimulation intensity was set at 120% RMT with the coil angled at 45 degrees and sine wave pulses provided through a figure-of-eight coil (in one case it is air core [Magpro] and in the other case is iron core [NeuroStar] ). Participants randomized to the sham rTMS group received the identical protocol without receiving the treatment. Using the NeuroStar, this involved a sham coil which replicated the noise of active treatment. For the Magpro, sham stimulation involved identical stimulation parameters but with the coil angled at 45 degrees away from the head.
Outcome assessment
Prior to the initial treatment, all patients underwent a baseline interview where they were asked questions in relation to their demographics, diagnosis and medical history. Participants then completed the selfreport primary and secondary outcome measures (described below). These outcome measures were repeated at the end of week 4 as well as at the onemonth follow-up. A trained rater who was blind to treatment type scored all assessments.
Primary outcomes
The primary outcome was pain severity and impact. This was assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ) (Melzack, 1987) , the Brief Pain Inventory (Short Form) (Cleeland and Ryan, 1994) and Numerical Pain Rating Scale (NPRS) measurements of pain intensity and pain unpleasantness. The SF-MPQ generates 3 primary scores: a 'Total Pain Rating Index' score based on sensory and affective descriptors rated by the participant on an intensity scale (e.g. 0 = none, 3 = severe); a 'Present Pain Intensity' score based on a 10 cm Visual Analogue Scale (0 = no pain, 10 = worst possible pain), and;
Lost to follow-up (n = 1) -Unable to contact an 'Evaluative Overall Intensity of Pain' score determined on a 6-point rating scale from 0 (none) to excruciating (5). The BPI is a self-report questionnaire assessing the severity of pain and daily impact and generates two scores representing 'pain severity' and 'pain interference'. The NPRS asked participants to rate over the last 24 h: (1) 'pain intensity' on a scale of 1 (no sensation) to 10 (the most intense sensation imaginable), and (2) 'pain unpleasantness' on a scale of 1 (not bad at all) to 10 (the most intense bad feeling imaginable).
We also assessed quality of life and current health status as coprimary outcomes, using the SF-36v2 (Ware, 2000) and the Fibromyalgia Impact Questionnaire (FIQ) (Bennett et al., 2009 ). The SF-36v2 is a generic self-report assessment of functional health and well-being and generates an overall 'physical health' and 'mental health' score. The FIQ is a disease-specific scale and includes an overall 'total' score with a maximum of 100 points where higher scores reflect greater impact of fibromyalgia.
Secondary outcomes
The secondary outcomes assessed the broader phenotype of fibromyalgia and allowed comparability of outcomes with other related trials. They included: the American College of Rheumatology Fibromyalgia Scale (ACR; Wolfe et al., 2010) , a self-report questionnaire assessing diagnosis and symptom severity measuring fatigue, sleep, cognitive and somatic complaints in patients with fibromyalgia; the Multidimensional Fatigue Inventory (MFI-20) (Smets et al., 1995) , which consists of five subscales ('general fatigue', 'physical fatigue', 'mental fatigue', 'reduced activity' and 'reduced motivation') where higher scores on a 5-item Likert scale indicate greater fatigue; the Pain Catastrophization Scale (PCS (Sullivan et al., 1995) ), a self-report measure exploring how people think and feel when they are in pain with greater 'total' scores reflecting higher pain catastrophization; the Beck Depression Inventory-II ((BDI-II; Beck et al., 1996) ); and the Beck Anxiety Inventory (BAI; Beck et al., 1988; ) .
At the one-month follow-up assessment, the Patients' Global Impression of Change (PGIC) scale was additionally used to assess the clinical significance of any treatment-related change in painspecific or broader health (Hurst and Bolton, 2004) . This required participants to (1) select an option between 1 (no change) and 7 (a great deal better, and a considerable improvement that has made all the difference) for 'perceived change' related to painful condition, and (2) to circle a number that matches 'perceived degree of change' since treatment. This scale was between 0 (much better) and 5 (no change) and 10 (much worse).
Treatment allocation blinding
A standard TMS blinding questionnaire was completed at follow-up where participants were asked to guess their treatment allocation (active or sham).
Side effects
Reported side effects were recorded throughout trial involvement. These were retrospectively grouped into the following categories: (1) site discomfort, (2) headache, (3) neck pain, (4) nausea, (5) dizziness and (6) other.
Data analysis
IBM SPSS Statistics for Windows (version 23, Armonk, NY: IBM Corp) was used. Independent ttests, Fisher's exact tests and chi-squared tests of independence were used to explore demographic and baseline differences between the active and sham groups (see Table 1 ).
Linear mixed-model analyses were then calculated for the dependent measures with fixed effects of group and time. An autoregressive first-order (AR(1)) covariance structure was determined to provide an appropriate fit for the data, and restricted maximum likelihood (REML) was used to estimate parameters. For any significant group x time interaction effects, post hoc analysis was conducted using Bonferroniadjusted pairwise comparisons of between-group differences in the dependent variable at each time point.
A responder analysis was also conducted using a Fisher's exact test to compare the frequency of participants between groups with at least a 30% improvement on the Present Pain Intensity (PPI) scale of the SF-MPQ from baseline to follow-up. We also calculated an odds ratio to compare the odds of being a responder in the active group versus sham treatment group. The PPI scale was selected for the responder analysis as pain intensity scales are universally accepted as an outcome for treatment efficacy in rTMS for pain trials (Klein et al., 2015) . A 30% improvement from baseline was used to identify responders to be consistent with what has been recommended to reflect a moderately important improvement by The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (Dworkin et al., 2008 (Dworkin et al., , 2009 ).
Finally, independent t-tests and Fisher's exact tests were also run to explore PGCI, blinding and side effects between the active and sham groups. A p value <0.05 was considered significant for all analyses.
Results
Participant demographics and baseline variables
The demographic characteristics and baseline assessments of the analysed sample are summarized in Table 1 . No significant differences were found between the active and sham treatment groups (p > 0.05) for these variables.
Mixed-model analysis
Results of the linear mixed-model analyses are presented in Table 2 .
Primary outcomes
A main effect of time was seen for all but one (the mental component summary of the SF-36v2) of the primary outcome measures (p < 0.05; see Table 2 ). However, no main effects of group or interaction effects between group and time were observed (p > 0.05) across these measures.
Secondary outcomes
A main effect of time was also observed for the majority of the secondary outcome measures (p < 0.05; see Table 2 ). In addition, a significant time x group interaction effect was observed on the Physical Fatigue scale of the MFI-20 (p = 0.002). Bonferroni-adjusted post hoc analysis found significantly lower fatigue at follow-up for the active compared to sham rTMS group (p = 0.045; see Fig. 2) . A time x group interaction effect was also seen (p = 0.015) for the General Fatigue scale. Bonferroni-adjusted post hoc comparisons again found significantly lower general fatigue at follow-up for the active compared to sham rTMS group (p = 0.023; see Fig. 3 ). No main effect of group was seen (p > 0.05) across these measures.
Responder analysis
The lack of a significant group x time interaction in the primary analysis may in part be explained by larger variation in change experienced by participants in the active treatment group (see Fig. 4 for percentage change scores from baseline to follow-up on the Present Pain Index within each group). A between-group comparison of participants who met responder status (at least a 30% reduction in Present Pain Intensity from baseline to follow-up) found that seven participants in active and one participant in sham had an at least 30% reduction (of a total of 21 participants with valid data at this time point; 11 active, 10 sham) a difference that was significant (Fisher's exact test p = 0.024, 2-sided). The odds of being a responder was 2.84 times greater with active treatment compared to sham (95% CI: 1.21-6.70). 
Patient perceived outcomes
Treatment allocation
There was no association between treatment groups and accuracy of predicted treatment group (Fisher's exact test p = 0.18, 2-sided).
Side effects
All participants tolerated rTMS well. Of the total sample, five (four active; one sham) reported site discomfort, seven reported headaches (four active; three sham), two reported neck pain (zero active; two sham), three reported nausea (one active; two sham), one reported dizziness (one active; zero sham) and two reported other (one active; one sham). There was no significant between-group difference in reported side effects (Fisher's exact test p > 0.05, 2-sided).
Discussion
In the current study, we examined the clinical efficacy of a 4-week rTMS treatment course applied to the dorsolateral prefrontal cortex (DLPFC) in patients with fibromyalgia. Although we did not observe an interaction effect between group and time in our primary outcome variables, we did identify that the likelihood of a minimum 30% improvement in pain intensity ratings was significantly (2.84 times) more likely in the active compared to sham group. In addition, we also found a significantly greater improvement on measures of fatigue in the active rTMS group compared to the sham group. We speculate that the increased frequency of analgesia following active compared to sham rTMS in our responder analysis was not identified between groups in the primary analysis due, in part, to the degree of response variability in our active treatment group. That is, while some people improved substantially, others did not or demonstrated worsening in pain intensity ratings. This is likely the result of inherent inter-and intraperson variability observed in response to brain stimulation (e.g. Hinder et al., 2014; Chew et al., 2015) . Contributing to such response variability is likely to be the individual variability (neural and perceptual) known to be present in the experience of pain (e.g. Mayhew et al., 2013; Fillingim, 2016) . It is therefore fundamental that work continues to explore the impact of intrinsic variability on the response to brain stimulation therapies for pain disorders.
Our results also indicated that the primary positive impact of our treatment course in patients with fibromyalgia was the improvement in physical and general fatigue. The Physical Fatigue subscale of the MFI-20 assesses physical sensations related to fatigue, whereas the General Fatigue scale assesses a combination of both physical and psychological fatigue functioning. In the active rTMS group, scores on these subscales dropped as much as almost 7 points at the follow-up period compared to baseline, whereas the sham treatment group scores were relatively unchanged. That these effects are identified at the follow-up time point suggests a potential delay in maximum treatment impact, and provision of follow-up assessment, may be fundamental to identifying improvement in this domain. This is supported by a case study of left DLPFC transcranial direct current stimulation (tDCS) on fatigue in multiple sclerosis, where improvements were greatest after 3 weeks of treatment with effects also observed 3 weeks post-treatment . This study is one of the few that target the DLPFC in rTMS trials for fibromyalgia. Of the 11 rTMS studies included in the recent meta-analysis of non-invasive brain stimulation trials for fibromyalgia (Hou et al., 2016) , only 4 targeted the DLPFC, with half targeting the left DLPFC. Of the two trials that targeted the left DLPFC, both were high frequency with one treatment course being 15 sessions over 4 weeks (Avery et al., 2015) , and the other a 2-week daily course (Short et al., 2011) . Therefore, the current trial is the longest left DLPFC rTMS treatment course in patients with fibromyalgia to date.
The DLPFC may be a highly relevant target for this and other pain disorders given that pain is a multidimensional experience, and the DLPFC plays a role in several cognitive, affective and sensory networks (Seminowicz and Moayedi, 2017) . Thus, modulation of this brain region may affect multiple symptom domains that contribute to the fibromyalgia syndrome. The substantial improvement in fatigue reported in the current study is of particular note given that, alongside widespread pain, fatigue is arguably the key symptom of fibromyalgia, and is often identified as the most impactful on patients (Williams & Kratz, 2016) . This may reflect the interlinked relationship of fatigue with other aspects of fibromyalgia, such as unrefreshed sleep, depressed mood and cognitive difficulties, including in attention (Vincent et al., 2013) . In fact, scores on the MFI have been identified to be highly correlated to quality of life measures and mood measures (Lin et al., 2009) , and there is strong evidence suggesting shared mechanisms between fatigue and depression (e.g. Bakshi et al., 2000) . Thus, the ability to improve fatigue symptoms is likely to have a consequential impact in other symptom domains (or vice versa). Future research may wish to further interrogate the relationship between the influence of rTMS on fatigue and related symptoms.
Despite its clinical relevance, fatigue is rarely a primary measure of potential interventions. As is the case in this study, the majority of brain stimulation studies that assess the effects on fatigue have done so as a secondary assessment. In a recent review of the treatment of fatigue by non-invasive brain stimulation methods, a total of 7 rTMS studies were identified to have included a clinical assessment of fatigue . Although these studies are too heterogeneous to truly inform the potential clinical role of non-invasive brain stimulation for fatigue, this review (and the results of the current study) suggests that there is enough evidence to warrant further investigation. Should noninvasive brain stimulation methods like rTMS prove to be successful in alleviating fatigue in fatiguerelated disorders, this will provide a potential therapeutic option for what is currently a difficult-to-treat symptom. The impact of this would be substantial given that fatigue is a common symptom in a number of pathologies beyond fibromyalgia where brain stimulation has already been explored as a potential treatment method (e.g. multiple sclerosis, depression, Parkinson's disease, amyotrophic lateral sclerosis, chronic fatigue syndrome and so on). The ability of brain stimulation methods to treat fatigue has also been explored in healthy populations where occupational conditions have been identified to affect cognition, with one study finding that left DLPFC tDCS following 36 h of wakefulness yielded superior improvement in cognition and mood compared with caffeine (McIntire et al., 2017) .
There are a number of strengths to the current investigation. These include the duration of treatment. Of the limited (and heterogeneous) clinical trial investigations of rTMS for fibromyalgia to date, the majority of these studies have had a short treatment course given over a short duration (e.g. 2 weeks) or a spread across a number of months. In the current trial, our rTMS paradigm was applied daily for 4 weeks (20 sessions). This was based largely on the approved rTMS treatments for other patient groups (i.e. depression), which commonly involve an acute left DLPFC treatment course for 4-6 weeks. In depression, clinical benefit generally emerges around 2-3 weeks of such a treatment course (Fitzgerald and Daskalakis, 2012) , suggesting that some of the rTMS fibromyalgia studies to date may be under-dosing patients and preventing clear determination of clinical relevance.
Another strength is the comprehensiveness of clinical outcomes. While pain is recommended as the primary outcome measure for chronic pain treatment interventions, other aspects of the multidimensional construct of pain may also be relevant. For instance, a 2015 meta-analysis of rTMS for fibromyalgia reported a moderate effect of improved QoL compared to sham rTMS (Knijnik et al., 2015) . They also found that while there was no significant effect on pain, there was an emerging trend. Improvement in broader fibromyalgia domains other than the experience of pain may therefore reflect the influence of rTMS on affective aspects of pain, which have a secondary benefit to decreasing pain sensation. Thus, in some cases, analgesic effects may emerge as secondary to the modulation of emotion-related neural networks. We also utilized a 'real-world' approach to patient inclusion. We did not exclude for depressive and anxiety symptoms (unless primary disorder), medication (unless unsafe for TMS) or sex (i.e. men included). Such exclusions have been present in most fibromyalgia brain stimulation studies, which ultimately limit the ecological validity and translation of this method.
Conversely, the present study is limited by a relatively small sample size. This may have impacted our ability to detect a between-group change in pain scores in the primary analysis. This study is also unable to determine whether DLPFC stimulation is any better than alternative brain sites such as M1. The current investigation would ideally have a comparative brain site (M1), or even dual stimulation of M1-DLPFC. The latter is particularly attractive given that it may theoretically result in the improvement of pain sensation as well as mood/fatigue simultaneously. Definitive studies of treatment sites are necessary to drive the field forward. This will require the use of neuro-navigation in future TMS clinical trials to ensure correct delivery to cortical targets and individualization of treatments. Finally, our primary finding was the improvement of fatigue. Notably, our patient sample (active and sham) had baseline fatigue scores above normed data for CFS-like and chronically unwell US sample groups (Lin et al., 2009) . The influence of rTMS on fatigue will require further interrogation, including whether the severity of the fatigue influences response (i.e. this effect is only seen in highly fatigued patients and not in more moderately fatigued samples).
Overall, the results of our study indicate that a 4-week daily treatment of left DLPFC stimulation may provide relief from fatigue associated with fibromyalgia. Our study also indicated that this treatment course was associated with a greater chance in reducing pain intensity than sham. These results highlight the potential for DLPFC stimulation to be a potentially relevant target for pain syndromes like fibromyalgia, with a broad symptom profile where symptoms beyond pain are recognized as disabling to sufferers. Second, it supports the need for comprehensive measures of treatment outcomes in brain stimulation trials in order to assess broader disorder phenomenology than pain alone. Ultimately, large sample studies with comparative treatment parameters are required to definitively evaluate rTMS as a therapeutic tool in fibromyalgia.
